Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IQV 
IQVIA Holdings Inc (IQV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: IQV (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
23 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $215.89
1 Year Target Price $215.89
| 14 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.03% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 31.83B USD | Price to earnings Ratio 27.09 | 1Y Target Price 215.89 |
Price to earnings Ratio 27.09 | 1Y Target Price 215.89 | ||
Volume (30-day avg) 23 | Beta 1.32 | 52 Weeks Range 134.65 - 248.03 | Updated Date 09/14/2025 |
52 Weeks Range 134.65 - 248.03 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.88% | Operating Margin (TTM) 13.39% |
Management Effectiveness
Return on Assets (TTM) 5.16% | Return on Equity (TTM) 19.79% |
Valuation
Trailing PE 27.09 | Forward PE 14.29 | Enterprise Value 45339400000 | Price to Sales(TTM) 2.03 |
Enterprise Value 45339400000 | Price to Sales(TTM) 2.03 | ||
Enterprise Value to Revenue 2.89 | Enterprise Value to EBITDA 13.54 | Shares Outstanding 170000000 | Shares Floating 161462600 |
Shares Outstanding 170000000 | Shares Floating 161462600 | ||
Percent Insiders 1.05 | Percent Institutions 102.1 |
Upturn AI SWOT
IQVIA Holdings Inc
Company Overview
History and Background
IQVIA Holdings Inc. was formed in 2017 through the merger of IMS Health and Quintiles. IMS Health, founded in 1954, focused on providing information and technology solutions to the healthcare industry. Quintiles, founded in 1982, was a leading provider of biopharmaceutical development and commercial outsourcing services. The merger created a global leader in integrated information and technology-enabled healthcare services.
Core Business Areas
- Technology & Analytics Solutions: Provides data, analytics, and technology platforms to support clinical and commercial operations for healthcare clients.
- Research & Development Solutions: Offers contract research services to biopharmaceutical companies, including clinical trial management, bioanalytical services, and consulting.
- Real-World Solutions: Delivers real-world evidence, outcomes research, and patient engagement services to improve healthcare decision-making.
Leadership and Structure
Ari Bousbib serves as the Chairman and CEO. The company operates with a global organizational structure, organized around its core business segments, with regional leadership teams reporting to the executive management team.
Top Products and Market Share
Key Offerings
- IMS OneKey: A comprehensive healthcare professional (HCP) database that provides detailed information on healthcare providers globally. This data helps pharmaceutical companies with targeted marketing and sales efforts. Competitors include Veeva Systems and Definitive Healthcare. Market Share is difficult to pin point but it is one of the leading databases for HCP data
- Orchestrated Customer Engagement (OCE): A CRM platform designed for the life sciences industry. OCE helps pharmaceutical companies manage customer interactions, track sales activities, and personalize marketing campaigns. Competitors include Veeva Systems CRM and Salesforce Health Cloud. Market Share is difficult to determine in this very competitive space but it is estimated to be a minor player.
- Clinical Trial Technologies: A suite of technology solutions designed to streamline clinical trial management. Competitors are Veeva Systems and Medidata Solutions. Market share is one of the largest.
Market Dynamics
Industry Overview
The healthcare industry is experiencing significant growth, driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. The market is highly competitive, with companies vying for market share in data analytics, clinical research, and technology solutions.
Positioning
IQVIA Holdings Inc. is positioned as a leading provider of integrated information and technology-enabled healthcare services. Its competitive advantages include its extensive data assets, global reach, and comprehensive suite of solutions.
Total Addressable Market (TAM)
The total addressable market for healthcare data and analytics, clinical research, and technology solutions is estimated to be hundreds of billions of dollars. IQVIA Holdings Inc. is well-positioned to capture a significant share of this market due to its comprehensive offerings and global presence.
Upturn SWOT Analysis
Strengths
- Extensive data assets
- Global reach
- Comprehensive suite of solutions
- Strong brand recognition
- Experienced management team
Weaknesses
- High debt level
- Integration risks associated with acquisitions
- Dependence on the biopharmaceutical industry
- Complex organizational structure
Opportunities
- Expanding into new markets
- Developing new products and services
- Acquiring complementary businesses
- Leveraging artificial intelligence and machine learning
- Increased demand for real-world evidence
Threats
- Increased competition
- Economic downturn
- Regulatory changes
- Data security breaches
- Loss of key personnel
Competitors and Market Share
Key Competitors
- VEEV
- LH
- DGX
- MEDP
Competitive Landscape
IQVIA Holdings Inc. has a strong competitive position due to its extensive data assets, global reach, and comprehensive suite of solutions. However, it faces competition from other large players in the healthcare industry, as well as smaller, specialized firms.
Major Acquisitions
DeepIntent
- Year: 2024
- Acquisition Price (USD millions): 800
- Strategic Rationale: Enhance Orchestrated Customer Engagement (OCE) platform with better audience insights and improve marketing effectiveness for healthcare clients.
Adverse Events, Inc.
- Year: 2021
- Acquisition Price (USD millions): 750
- Strategic Rationale: Strengthen Pharmacovigilance.
Growth Trajectory and Initiatives
Historical Growth: IQVIA Holdings Inc. has experienced consistent revenue growth over the past several years, driven by strong demand for its data and analytics, clinical research, and technology solutions.
Future Projections: Future growth is projected to be driven by continued demand for its core offerings, as well as expansion into new markets and development of new products and services. Analyst estimates vary depending on broader market and economic conditions.
Recent Initiatives: Recent strategic initiatives include acquisitions to expand its capabilities, investments in artificial intelligence and machine learning, and partnerships to expand its reach.
Summary
IQVIA is a strong company with a leading position in healthcare data and analytics, driven by its comprehensive solutions. It benefits from growing demand in the industry, but its high debt and integration risks need monitoring. Future success hinges on leveraging AI and expanding into new markets while managing competition and potential economic downturns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- IQVIA Holdings Inc. Investor Relations
- Third Party Market Research Reports
- Company Filings
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions are subject to change. Financial figures are subject to change; consult IQVIA's official filings for the most up-to-date information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IQVIA Holdings Inc
Exchange NYSE | Headquaters Durham, NC, United States | ||
IPO Launch date 2013-05-09 | CEO & Chairman Mr. Ari Bousbib | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 90000 | Website https://www.iqvia.com |
Full time employees 90000 | Website https://www.iqvia.com | ||
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.